2019ESC/EAS Guidelines for the management ofdyslipidaemias

Guidelines summarize and evaluate all available evidence at the time of the writing process on a particular issue with the aim of assisting physicians in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk–beneﬁt ratio

ESc/EAS Guidelines for the management of dyslipidemias

The ESC Guidelines represent the views of the ESC and the EAS, and were arrived at after careful consideration of the available evidence at the time they were written Health professionals are encouraged to take them fully into account when exercising their clinical judgement The guidelines do not, however, override the individual

2016 ESC/EAS Guidelines on the management of dyslipidaemias

2016 ESC/EAS Guidelines on the management of dyslipidaemias European Heart Journal 2016 - doi:10 1093/eurheartj/ehv272

Guidlies for the diagnosis and management of Dyslipidemia for

2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults > 18 Years Old - February 2008 – Page 2 Treatment Overview of Dyslipidemia Dyslipidemia is a powerful risk factor for coronary heart disease (CHD) Clinical trials conclusively have demonstrated that treatment of lipid disorders can reduce CHD morbidity and mortality

ACC/AHA DYSLIPIDEMIA GUIDELINES

Risk Management –Primary prevent In adults 40 to 75 years of age without diabetes mellitus and with LDL- C levels ≥70 mg/dL - 189 mg/dL (≥1 8 -4 9 mmol/L), at a

2019ESC/EAS Guidelines for the management ofdyslipidaemias

Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies Health professionals are encouraged to take the ESC/EAS Guidelines fully into account when exercising their clinical judgment, as well as in the

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL

dyslipidemias The most common primary dyslipidemias are elevated Lp(a) and mixed dyslipidemia, a combina-tion of elevated levels of both cholesterol and triglycer-ides This combination is also seen in 2 much less common states: familial combined hyperlipidemia and dysbetalipo-proteinemia Familial combined hyperlipidemia is defined

Dyslipidemia Management - Summary How do I assess Dyslipidemia?

-stress management -limitations on alcohol consumption -these behaviours should be universally applied to all patients for the prevention of chronic disease and are outlined under Health Behaviours under treatments for dyslipidemias Patients should be advised to stop statin therapy and contact prescribing health care provider if

[PDF] LES ESCALIERS

[PDF] E coli - Anses

[PDF] 19 La traite des esclaves - Académie de Nancy-Metz

[PDF] L 'escompte Les moyens de paiement concernés L 'escompte

[PDF] l 'Escompte - Marketing Thus

[PDF] l 'Escompte - Marketing Thus

[PDF] mastère spécialisé marketing et communication - Top Universities

[PDF] BASES DE L 'ESCRIME A L 'EPEE LONGUE DE - WordPresscom

[PDF] Dossier escrime 1

[PDF] TALLERES PARA PADRES DE FAMILIA Taller N° 1 Familia y

[PDF] Manual didáctico para la Escuela de Padres - Centro de Solidaridad

[PDF] Manual didáctico para la Escuela de Padres - Centro de Solidaridad

[PDF] FUNCIONALISMO: Características principales: Principales

[PDF] cuadro sinóptico de las diferentes escuelas psicológicas

[PDF] cuadro sinóptico de las diferentes escuelas psicológicas

2019 ESC/EAS Guidelines for the management

of dyslipidaemias:lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the

European Society of Cardiology (ESC) and European

Atherosclerosis Society (EAS)

Authors/Task Force Members: Franc¸ois Mach* (Chairperson) (Switzerland), Colin Baigent* (Chairperson) (United Kingdom), Alberico L. Catapano 1 (Chairperson) (Italy), Konstantinos C. Koskinas (Switzerland), Manuela Casula 1 (Italy), Lina Badimon (Spain), M. John Chapman 1 (France), Guy G. De Backer (Belgium), Victoria Delgado (Netherlands), Brian A. Ference (United Kingdom), Ian M. Graham (Ireland), Alison Halliday (United Kingdom), Ulf Landmesser (Germany), Borislava Mihaylova (United Kingdom), Terje R. Pedersen (Norway),

Gabriele Riccardi

1 (Italy), Dimitrios J. Richter (Greece), Marc S. Sabatine (United

States of America), Marja-Riitta Taskinen

1 (Finland), Lale Tokgozoglu 1 (Turkey),

Olov Wiklund

1 (Sweden) The three chairpersons contributed equally to the document.

*Corresponding authors: Franc¸ois Mach, Cardiology Department, Geneva University Hospital, 4 Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland. Tel:þ41 223 727 192,

Fax:þ41 223 727 229, Email: francois.mach@hcuge.ch. Colin Baigent, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive,

Oxford OX3 7LF, United Kingdom. Tel:þ44 1865 743 741, Fax:þ44 1865 743 985, Email: colin.baigent@ndph.ox.ac.uk. Alberico L. Catapano, Department of Pharmacological

and Biomolecular Sciences, University of Milan, Via Balzaretti, 9, 20133 Milan, and Multimedica IRCCS, Milan, Italy. Tel:þ39 02 5031 8401, Fax:þ39 02 5031 8386,

Email: alberico.catapano@unimi.it.

ESC Committee for Practice Guidelines (CPG), National Cardiac Societies document reviewers and Author/Task Force Member affiliations: listed in the Appendix.

Representing the EAS.

ESC entities having participated in the development of this document:

Associations:Acute Cardiovascular Care Association (ACCA), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular

Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Councils:Council for Cardiology Practice, Council on Hypertension, Council on Stroke.

Working Groups:Aorta and Peripheral Vascular Diseases, Atherosclerosis and Vascular Biology, Cardiovascular Pharmacotherapy, e-Cardiology, Thrombosis.

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of

the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of awritten request to

Oxford University Press, the publisher of theEuropean Heart Journaland the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oxfordjour-

nals.org).

Disclaimer. The ESC/EAS Guidelines represent the views of the ESC and EAS, and were produced after careful consideration of the scientific and medical knowledge,and the

evidence available at the time of their publication. The ESC and EAS is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC/EAS

Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic

strategies. Health professionals are encouraged to take the ESC/EAS Guidelines fully into account when exercising their clinical judgment, as wellas in the determination and the

implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC/EAS Guidelines do not override, in any way whatsoever, the individual responsibil-

ity of health professionals to make appropriate and accurate decisions in consideration of each patient"s health condition and in consultation withthat patient and, where appro-

priate and/or necessary, the patient"s caregiver. Nor do the ESC/EAS Guidelines exempt health professionals from taking into full and careful consideration the relevant official

updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient"s case in light of the scientifically accepted data pur-

suant to their respective ethical and professional obligations. It is also the health professional"s responsibility to verify the applicable rulesand regulations relating to drugs and

medical devices at the time of prescription.

For permissions please email: journals.permissions@oup.com.

European Heart Journal (2019)00,1?78

ESC/EAS GUIDELINES

doi:10.1093/eurheartj/ehz455Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz455/5556353 by guest on 31 August 2019

Document Reviewers: Christian Mueller (ESC Review Coordinator) (Switzerland), Heinz Drexel (EAS Review Coordinator) (Austria), Victor Aboyans (France), Alberto Corsini 1 (Italy), Wolfram Doehner (Germany), Michel Farnier (France), Bruna Gigante (Sweden), Meral Kayikcioglu 1 (Turkey),

Goran Krstacic (Croatia), Ekaterini Lambrinou (Cyprus), Basil S. Lewis (Israel), Josep Masip (Spain),

Philippe Moulin

1 (France), Steffen Petersen (United Kingdom), Anna Sonia Petronio (Italy),

Massimo Francesco Piepoli (Italy), Xavier Pint

?o 1 (Spain), Lorenz Raber (Switzerland), Kausik K. Ray 1 (United Kingdom),?Zeljko Reiner 1 (Croatia), Walter F. Riesen (Switzerland), Marco Roffi (Switzerland), Jean-Paul Schmid (Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United

Kingdom), Erik Stroes

1 (Netherlands), Isabella Sudano (Switzerland), Alexandros D. Tselepis 1 (Greece),

Margus Viigimaa

1 (Estonia), Cecile Vindis (France), Alexander Vonbank (Austria), Michal Vrablik 1 (Czech

Republic), Mislav Vrsalovic (Croatia), Jose´ Luis Zamorano Gomez (Spain), Jean-Philippe Collet (ESC CPG

Supervisor) (France)

The disclosure forms of all experts involved in the development of these Guidelines are available on the

ESC websitewww.escardio.org/guidelines

For the Supplementary Data which include background information and detailed discussion of the data

that have provided the basis for the Guidelines seehttps://academic.oup.com/eurheartj/article-lookup/doi/

Keywords

Guidelines

dyslipidaemias cholesterol triglycerides low-density lipoproteins high-density lipopro- teins apolipoprotein B lipoprotein(a) lipoprotein remnants total cardiovascular risk treatment (lifestyle) treatment (drugs) treatment (adherence) very low-density lipoproteins familial hypercholesterolaemia

Abbreviationsandacronyms ........................................ 4

1Preamble......................................................... 6

2Introduction...................................................... 8

2.1Whatisnewinthe2019Guidelines? .......................... 8

3Whatiscardiovasculardiseaseprevention? ........................ 8

3.1Definitionandrationale ....................................... 8

3.2 Developmentofthe JointTaskForceGuidelinesforthe

managementofdyslipidaemias.................................... 8

4Totalcardiovascularrisk .......................................... 8

4.1Totalcardiovascularriskestimation ........................... 8

4.1.1 Rationaleforassessingtotal cardiovasculardisease risk ... . 11

4.1.2 Howtousethe riskestimationcharts . .. ... .. ... ... .. ... . 14

4.2Risklevels ................................................... 15

4.2.1 Role ofnon-invasive cardiovascularimaging

diseaserisk ................................................... 16

4.2.2Risk-basedinterventionstrategies ........................ 17

5Lipidsandlipoproteins ........................................... 17

5.1Biologicalroleoflipidsandlipoproteins....................... 17

5.2 Role oflipidsandlipoproteinsinthe pathophysiology of

atherosclerosis ................................................. 17

5.3 Evidence forthe causal effectsoflipidsandlipoproteinson

theriskofatheroscleroticcardiovasculardisease ... .. ... ... .. ... . 18

5.3.1 Low-densitylipoproteincholesterolandrisk of

atherosclerosis ............................................... 18

5.3.2 Triglyceride-richlipoproteinsandrisk ofatherosclerosis . . 18

5.3.3 High-densitylipoprotein cholesterolandrisk of

atherosclerosis ............................................... 195.3.4 Lipoprotein(a) andriskofatherosclerosis ... ... .. ... .. ... 19

5.4Laboratorymeasurementoflipidsandlipoproteins . .. ... .. ... 19

5.4.1Lipoproteinmeasurement ............................... 19

5.4.2Lipidmeasurements ..................................... 20

5.4.3Fastingornon-fasting? ................................... 20

estimateriskofatheroscleroticcardiovasculardisease .. .. ... .. ... 20

6Treatmenttargetsandgoals...................................... 21

7Lifestylemodificationsto improve theplasmalipidprofile .. ... .. ... 22

7.1Influence oflifestyleontotalcholesterolandlow-density

lipoproteincholesterollevels .................................... 24

7.2Influenceoflifestyleontriglyceridelevels ..................... 24

7.3Influence oflifestyleonhigh-density lipoprotein cholesterol

levels ........................................................... 25

7.4Lifestyle recommendationsto improve theplasmalipid

profile .......................................................... 25

7.4.1Bodyweightandphysicalactivity ......................... 25

7.4.2Dietaryfat .............................................. 25

7.4.3Dietarycarbohydrateandfibre .......................... 26

7.4.4Alcohol ................................................. 26

7.4.5Smoking ................................................ 26

treatmentofdyslipidaemias ..................................... 26

7.5.1Phytosterols ............................................ 26

7.5.2Monacolinandredyeastrice............................. 26

7.5.3Dietaryfibre ............................................ 27

7.5.4Soy ..................................................... 27

7.5.5Policosanolandberberine ............................... 27

7.5.6n-3unsaturatedfattyacids ............................... 27

2ESC/EAS GuidelinesDownloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz455/5556353 by guest on 31 August 2019

8Drugsfortreatmentofdyslipidaemias ............................ 27

8.1Statins ...................................................... 27

8.1.1Mechanismofaction .................................... 27

8.1.2Effectsonlipids.......................................... 27

8.1.2.1Low-densitylipoproteincholesterol...................... 27

8.1.2.2Triglycerides......................................... 27

8.1.2.3High-densitylipoproteincholesterol..................... 27

8.1.2.4Lipoprotein(a)........................................ 27

8.1.3Othereffectsofstatins .................................. 28

8.1.3.1Effectoncardiovascularmorbidityandmortality.......... 28

8.1.4 Adverseeffectsandinteractionsofstatins .. .. ... ... .. ... . 28

8.1.4.1Adverseeffectsonmuscle............................. 28

8.1.4.2Adverseeffectsontheliver............................. 29

8.1.4.3Increasedriskofnew-onsetdiabetesmellitus............. 29

8.1.4.4Increasedriskofhaemorrhagicstroke................... 29

8.1.4.5Adverseeffectsonkidneyfunction...................... 29

8.1.4.6Interactions.......................................... 29

8.2Cholesterolabsorptioninhibitors ............................ 30

8.2.1Mechanismofaction .................................... 30

8.2.2Effectsonlipids.......................................... 30

8.2.3 Effect oncardiovascularmorbidityandmortality . ... .. ... . 30

8.2.4Adverseeffectsandinteractions ......................... 30

8.3Bileacidsequestrants ........................................ 30

8.3.1Mechanismofaction .................................... 30

8.3.2Effectsonlipids.......................................... 30

8.3.3 Effect oncardiovascularmorbidityandmortality . ... .. ... . 30

8.3.4Adverseeffectsandinteractions ......................... 31

8.4 Proprotein convertasesubtilisin/kexin type9 inhibitors .. .. ... . 31

8.4.1Mechanismofaction .................................... 31

8.4.2Effectsonlipids.......................................... 31

8.4.2.1Low-densitylipoproteincholesterol...................... 31

8.4.2.2Triglyceridesandhigh-densitylipoproteincholesterol...... 31

8.4.2.3Lipoprotein(a)........................................ 31

8.4.3 Effect oncardiovascularmorbidityandmortality . ... .. ... . 31

8.4.4Adverseeffectsandinteractions ......................... 32

8.5Lomitapide .................................................. 32

8.6Mipomersen ................................................ 32

8.7Fibrates ..................................................... 32

8.7.1Mechanismofaction .................................... 32

8.7.2Effectsonlipids.......................................... 32

8.7.3 Effect oncardiovascularmorbidityandmortality . ... .. ... . 33

8.7.4Adverseeffectsandinteractions ......................... 33

8.8n-3fattyacids ............................................... 33

8.8.1Mechanismofaction .................................... 33

8.8.2Effectsonlipids.......................................... 33

8.8.3 Effect oncardiovascularmorbidityandmortality . ... .. ... . 33

8.8.4Safetyandinteractions................................... 34

8.9Nicotinicacid ............................................... 34

8.10Cholesteryl estertransferprotein inhibitors ... .. ... ... .. ... . 34

8.11Futureperspectives ........................................ 34

8.11.1Newapproachestoreducelow-density lipoprotein

cholesterol................................................... 34 lipoproteinsandtheirremnants ............................... 34

8.11.3Newapproachestoincrease high-densitylipoprotein

cholesterol................................................... 35

8.11.4Newapproachestoreducelipoprotein(a) levels ... .. ... . 358.12Strategiestocontrolplasmacholesterol..................... 35

8.13Strategiestocontrolplasmatriglycerides .................... 35

9Management ofdyslipidaemiasin differentclinical settings . ... .. ... 38

9.1Familialdyslipidaemias ....................................... 38

9.1.1Familialcombinedhyperlipidaemia ....................... 38

9.1.2Familialhypercholesterolaemia .......................... 38

9.1.2.1Heterozygousfamilialhypercholesterolaemia............ 38

9.1.2.2Homozygousfamilialhypercholesterolaemia............ 41

9.1.2.3Familialhypercholesterolaemiainchildren............... 41

9.1.3 Familialdysbetalipoproteinaemia .. .. ... .. ... ... .. ... .. ... 41

9.1.4 Geneticcausesofhypertriglyceridaemia .. ... ... .. ... .. ... 41

9.1.4.1 Action to prevent acute pancreatitis in severe

hypertriglyceridaemia........................................ 41

9.1.5 Othergeneticdisordersoflipoproteinmetabolism .. .. ... 42

9.2Women .................................................... 42

9.2.1 Effectsofstatinsinprimary andsecondary prevention .. ... 42

9.2.2Non-statinlipid-loweringdrugs .......................... 42

9.2.3Hormonetherapy ....................................... 42

9.3Olderpeople................................................ 42

9.3.1 Effectsofstatinsinprimary andsecondary prevention .. ... 43

9.3.2Adverseeffects,interactions,andadherence.............. 43

9.4Diabetesandmetabolicsyndrome ........................... 43

9.4.1 Specific featuresofdyslipidaemiain insulin resistance

andtype2diabetes ........................................... 43

9.4.2Evidenceforlipid-loweringtherapy ...................... 44

9.4.2.1Low-densitylipoprotein cholesterol...................... 44

9.4.2.1Triglyceridesandhigh-densitylipoproteincholesterol...... 44

9.4.3Type1diabetes ......................................... 45

9.4.4 Managementofdyslipidaemiaforpregnantwomen

withdiabetes ................................................. 45

9.5Patientswith acutecoronary syndromesandpatients

undergoingpercutaneouscoronaryintervention ................. 46

9.5.1 Lipid-loweringtherapy in patientswithacute

coronarysyndromes ......................................... 46

9.5.1.1 Statins.............................................. 46

9.5.1.2 Ezetimibe........................................... 46

9.5.1.3 Proprotein convertase subtilisin/kexin type 9 inhibitors..... 46

9.5.1.4n-3 polyunsaturatedfattyacids......................... 47

9.5.1.5Cholesterylestertransferproteininhibitors............... 47

9.5.2 Lipid-loweringtherapy in patientsundergoing

percutaneouscoronaryintervention .......................... 47

9.6Stroke ...................................................... 48

9.7Heartfailureandvalvulardiseases ............................ 48

9.7.1 Prevention ofincidentheartfailureincoronaryartery

diseasepatients .............................................. 48

9.7.2Chronicheartfailure .................................... 48

9.7.3Valvularheartdiseases................................... 48

9.8Chronickidneydisease ...................................... 49

9.8.1 Lipoproteinprofileinchronic kidneydisease . ... .. ... .. ... 49

9.8.2 Evidenceforrisk reductionthrough statin-based

therapyinpatientswithchronickidneydisease................. 49

9.8.3 Safetyoflipidmanagementin patientswithchronic

kidneydisease ................................................ 49

9.9Transplantation ............................................. 50

9.10Peripheralarterialdisease................................... 50

9.10.1Lowerextremityarterialdisease ........................ 50

9.10.2Carotidarterydisease .................................. 51

ESC/EAS Guidelines3Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz455/5556353 by guest on 31 August 2019

[PDF] 2019ESC/EAS Guidelines for the management ofdyslipidaemias